Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors
- Published on 03/28/2024
- Reading time: 5 min.
Shijubou Naoki 1,2, Sumi Toshiyuki 2,3, Kubo Terufumi 1, Sasaki Kenta 1, Tsukahara Tomohide 1, Kanaseki Takayuki 1, Murata Kenji 1, Keira Yoshiko 4, Terai Kotomi 4, Ikeda Tatsuru 4, Yamada Yuichi 3, Chiba Hirofumi 2, Hirohashi Yoshihiko 1, Torigoe Toshihiko 1
1 https://ror.org/01h7cca57 Department of Pathology Sapporo Medical University School of Medicine 060-8556 Sapporo Japan
2 https://ror.org/01h7cca57 Department of Respiratory Medicine and Allergology Sapporo Medical University School of Medicine Sapporo Hokkaido Japan
3 Department of Respiratory Medicine Hakodate Goryoukaku Hospital Hakodate Hokkaido Japan
4 Department of Pathology Hakodate Goryoukaku Hospital Hakodate Hokkaido Japan
Abstract
Purpose Although immune checkpoint inhibitors (ICIs), together with cytotoxic chemotherapy (chemoimmunotherapy), have been adapted for the initial treatment of extensive-disease small-cell lung cancer (ED-SCLC), they have achieved limited success. In ED-SCLC, a subtype of SCLC, the expression of immune-related molecules and clinical data are not well understood in relation to ICI treatment efficiency.
Methods We examined lung biopsy specimens from patients...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
